Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis

INTRODUCTION: The EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo for the treatment of renal angiomyolipomas associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM). This post hoc analysis of EXIST-2 study aimed to assess angiom...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissler, John J., Nonomura, Norio, Budde, Klemens, Zonnenberg, Bernard A., Fischereder, Michael, Voi, Maurizio, Louveau, Anne-Laure, Herbst, Fabian, Bebin, E. Martina, Curatolo, Paolo, Zonta, Andrea, Belousova, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128468/
https://www.ncbi.nlm.nih.gov/pubmed/30192751
http://dx.doi.org/10.1371/journal.pone.0201005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128468/
https://www.ncbi.nlm.nih.gov/pubmed/30192751
http://dx.doi.org/10.1371/journal.pone.0201005

Ejemplares similares